脊髓损伤
神经科学
神经炎症
再生(生物学)
医学
胶质增生
背景(考古学)
轴突
移植
小RNA
胶质瘢痕
中枢神经系统
脊髓
生物
病理
外科
细胞生物学
古生物学
生物化学
疾病
基因
作者
Serena Silvestro,Emanuela Mazzon
出处
期刊:Cells
[MDPI AG]
日期:2022-07-12
卷期号:11 (14): 2177-2177
标识
DOI:10.3390/cells11142177
摘要
Spinal cord injury (SCI) represents a devastating injury to the central nervous system (CNS) that is responsible for impaired mobility and sensory function in SCI patients. The hallmarks of SCI include neuroinflammation, axonal degeneration, neuronal loss, and reactive gliosis. Current strategies, including stem cell transplantation, have not led to successful clinical therapy. MiRNAs are crucial for the differentiation of neural cell types during CNS development, as well as for pathological processes after neural injury including SCI. This makes them ideal candidates for therapy in this condition. Indeed, several studies have demonstrated the involvement of miRNAs that are expressed differently in CNS injury. In this context, the purpose of the review is to provide an overview of the pre-clinical evidence evaluating the use of miRNA therapy in SCI. Specifically, we have focused our attention on miRNAs that are widely associated with neuronal and axon regeneration. “MiRNA replacement therapy” aims to transfer miRNAs to diseased cells and improve targeting efficacy in the cells, and this new therapeutic tool could provide a promising technique to promote SCI repair and reduce functional deficits.
科研通智能强力驱动
Strongly Powered by AbleSci AI